DekaBank Deutsche Girozentrale’s Adaptimmune Therapeutics ADAP Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-42,000	Closed	-$215K	–	1417
2021 Q3	$215K	Hold	42,000	–	–	﹤0.01%	1197
2021 Q2	$181K	Hold	42,000	–	–	﹤0.01%	1240
2021 Q1	$209K	Hold	42,000	–	–	﹤0.01%	1176
2020 Q4	$215K	Buy	+42,000	New	+$228K	﹤0.01%	1171
2019 Q3	–	Sell	-89,000	Closed	-$355K	–	991
2019 Q2	$355K	Buy	89,000 +64,500	+263%	+$263K	﹤0.01%	958
2019 Q1	$265K	Sell	24,500 -20,000	-45%	-$93.1K	﹤0.01%	1005
2018 Q4	$216K	Buy	44,500 +20,000	+82%	+$148K	﹤0.01%	958
2018 Q3	$265K	Hold	24,500	–	–	﹤0.01%	1027
2018 Q2	$294K	Hold	24,500	–	–	﹤0.01%	997
2018 Q1	$257K	Buy	+24,500	New	+$214K	﹤0.01%	959

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DekaBank Deutsche Girozentrale's ADAP Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 42,000 shares — an estimated $215K sold.

DekaBank Deutsche Girozentrale first reported a position in ADAP in Q1 2018 and held it in 10 quarters. The position peaked at $355K in Q2 2019. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

DekaBank Deutsche Girozentrale reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 42,000 Adaptimmune Therapeutics shares in Q4 2021, an estimated $215K.
DekaBank Deutsche Girozentrale first reported a position in Adaptimmune Therapeutics in Q1 2018 and held it in 10 quarters.
DekaBank Deutsche Girozentrale's Adaptimmune Therapeutics position peaked at $355K in Q2 2019.
85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.